1. Market Research
  2. > Business Services
  3. > Research and Development Market Trends
  4. > Advancell - Product Pipeline Review - 2014

Advancell - Product Pipeline Review - 2014

  • November 2014
  • -
  • Global Markets Direct
  • -
  • 32 pages

Advancell - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘Advancell - Product Pipeline Review - 2014’, provides an overview of the Advancell’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Advancell’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Advancell including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Advancell’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Advancell’s pipeline products

Reasons to buy

- Evaluate Advancell’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Advancell in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Advancell’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Advancell and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Advancell
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Advancell and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Advancell - Product Pipeline Review - 2014
Table of Contents

Advancell Snapshot 5
Advancell Overview 5
Key Information 5
Key Facts 5
Advancell - Research and Development Overview 6
Key Therapeutic Areas 6
Advancell - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
Pipeline Products - Out-Licensed Products 12
Out-Licensed Products/Combination Treatment Modalities 13
Advancell - Pipeline Products Glance 14
Advancell - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
Advancell - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Advancell - Drug Profiles 17
acadesine 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
ANs-29 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
ANs-31 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
ANs-40 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
ANS-401 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
ANS-403 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
Advancell - Pipeline Analysis 24
Advancell - Pipeline Products by Target 24
Advancell - Pipeline Products by Route of Administration 25
Advancell - Pipeline Products by Molecule Type 26
Advancell - Pipeline Products by Mechanism of Action 27
Advancell - Recent Pipeline Updates 28
Advancell - Dormant Projects 29
Advancell - Locations And Subsidiaries 30
Head Office 30
Appendix 31
Methodology 31
Coverage 31
Secondary Research 31
Primary Research 31
Expert Panel Validation 31
Contact Us 32
Disclaimer 32

List of Tables

Advancell, Key Information 5
Advancell, Key Facts 5
Advancell - Pipeline by Indication, 2014 7
Advancell - Pipeline by Stage of Development, 2014 8
Advancell - Monotherapy Products in Pipeline, 2014 9
Advancell - Partnered Products in Pipeline, 2014 10
Advancell - Partnered Products/ Combination Treatment Modalities, 2014 11
Advancell - Out-Licensed Products in Pipeline, 2014 12
Advancell - Out-Licensed Products/ Combination Treatment Modalities, 2014 13
Advancell - Phase II, 2014 14
Advancell - Phase I, 2014 15
Advancell - Preclinical, 2014 16
Advancell - Pipeline by Target, 2014 24
Advancell - Pipeline by Route of Administration, 2014 25
Advancell - Pipeline by Molecule Type, 2014 26
Advancell - Pipeline Products by Mechanism of Action, 2014 27
Advancell - Recent Pipeline Updates, 2014 28
Advancell - Dormant Developmental Projects,2014 29

List of Figures

Advancell - Pipeline by Top 10 Indication, 2014 7
Advancell - Pipeline by Stage of Development, 2014 8
Advancell - Monotherapy Products in Pipeline, 2014 9
Advancell - Partnered Products in Pipeline, 2014 10
Advancell - Out-Licensed Products in Pipeline, 2014 12
Advancell - Pipeline by Top 10 Target, 2014 24
Advancell - Pipeline by Top 10 Route of Administration, 2014 25
Advancell - Pipeline by Top 10 Molecule Type, 2014 26
Advancell - Pipeline Products by Top 10 Mechanism of Action, 2014 27

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016’, provides in depth analysis on Integrin Alpha 7 (ITGA7) ...

Pulmonary Fibrosis - Pipeline Review, H2 2016

Pulmonary Fibrosis - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Pulmonary Fibrosis - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Pulmonary Fibrosis - Pipeline Review, H2 2016’, provides an overview of the Pulmonary Fibrosis pipeline landscape. ...

Cognitive Impairment - Pipeline Review, H2 2016

Cognitive Impairment - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Cognitive Impairment - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cognitive Impairment - Pipeline Review, H2 2016’, provides an overview of the Cognitive Impairment pipeline landscape. ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.